Literature DB >> 8674041

MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.

A H Reitmair1, J C Cai, M Bjerknes, M Redston, H Cheng, M T Pind, K Hay, A Mitri, B V Bapat, T W Mak, S Gallinger.   

Abstract

Accelerated intestinal tumorigenesis is probable in hereditary nonpolyposis colorectal cancer, a condition associated with germ line DNA mismatch repair (MMR) gene defects, and is believed to be caused by rapid accumulation of replication errors in critical genes, such as the APC (adenomatous polyposis coli) tumor suppressor gene. To study the potential contribution of MMR genes to accelerated intestinal tumorigenesis, we crossed the Min mouse, heterozygous for a germ line mutation of Apc, with an MMR gene (Msh2)-deficient mouse. MSH2 deficiency resulted in the development of many colonic aberrant crypt foci, as well as reduced survival of the mice, secondary to both a greater number and more rapidly developing adenomas. The mechanism of inactivation of the wild-type Apc allele depended on MSH2 status. In the presence of functional MSH2, all tumors demonstrated loss of heterozygosity. In contrast, whereas all adenomas were APC negative by immunostaining, only 5 of 34 adenomas from Apc+/-/Msh2-/- mice demonstrated loss of heterozygosity of the wild-type Apc allele, suggesting that somatic Apc mutations are responsible for the additional tumors. These findings provide evidence for the important role of MMR genes in accelerated intestinal tumorigenesis, thus supporting more aggressive surveillance strategies to prevent colorectal cancer in hereditary nonpolyposis colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674041

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 2.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

3.  Giving APCmin tumours a SPARC.

Authors:  Alex Gregorieff; Hans Clevers
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

4.  Genetic Manipulation of Homologous Recombination In Vivo Attenuates Intestinal Tumorigenesis.

Authors:  Michael A McIlhatton; Kevin Murnan; Daniel Carson; Gregory P Boivin; Carlo M Croce; Joanna Groden
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-23

Review 5.  Theories of carcinogenesis: an emerging perspective.

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

6.  Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination.

Authors:  Carol E Schrader; Sean P Bradley; Joycelyn Vardo; Sofia N Mochegova; Erin Flanagan; Janet Stavnezer
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

Review 7.  Murine models of colorectal cancer.

Authors:  Joshua M Uronis; David W Threadgill
Journal:  Mamm Genome       Date:  2009-05-15       Impact factor: 2.957

Review 8.  Aberrant crypt foci as microscopic precursors of colorectal cancer.

Authors:  Lei Cheng; Mao-De Lai
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 9.  Animal models of colorectal cancer.

Authors:  Robert L Johnson; James C Fleet
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

10.  An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.

Authors:  Melanie H Kucherlapati; Kyeryoung Lee; Andrew A Nguyen; Alan B Clark; Harry Hou; Andrew Rosulek; Hua Li; Kan Yang; Kunhua Fan; Martin Lipkin; Roderick T Bronson; Linda Jelicks; Thomas A Kunkel; Raju Kucherlapati; Winfried Edelmann
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.